
Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Scroll through images from this year’s Cancer Crosslinks, a full-day educational programme and networking event tailored to the oncology community.
Want to learn more about Cancer Crosslinks? Please visit: https://www.cancercrosslinks.com/
Jan 28, 2025
Sofia Linden
The 17th Cancer Crosslinks was held at Oslo Cancer Cluster Innovation Park last Thursday. This year's edition brought the focus on how innovations in basic research, translational research and technology can improve cancer patients' lives.
Distinguished speakers from the UK, US, and the Nordics addressed emerging diagnostic and treatment options for solid and haematological cancers. The topics of the educational talks ranged from developments in tumour-agnostic therapies and precision medicine, to improvements in cell therapy and recent digital innovations.
Marine Jeanmougin, Lead EU Affairs and Digital Innovations at Oslo Cancer Cluster, commented:
“We see cancer differently and treat it differently than we did ten years ago, as Magnus Essand stated during his talk, capturing the essence of Cancer Crosslinks 2025. This was further illustrated by Vivek Subbiah, Ruth Plummer, and Inge Marie Svane, who showed how advances in molecular biology and immunology are driving innovative cancer treatments.
“With upcoming digital solutions and data-sharing infrastructures, more changes are on the horizon, as Ingrid Stenstadvold Ross and Joel Hedlund pointed out. The next decade offers unique opportunities in cancer care, and we will continue to use Cancer Crosslinks as a forum for learning and collaboration.”
The event attracted approximately 300 attendees who wanted to learn the latest from the international cancer research front. Academics, clinicians, patient spokespeople, health bureaucrats and industry representatives from different parts of Norway and abroad were among the participants.
Charlotte Wu Homme, Head of Membership and Events at Oslo Cancer Cluster, commented:
“Oslo Cancer Cluster (OCC) is a membership organization dedicated to improving the lives of cancer patients. Cancer Crosslinks is one way OCC contributes towards knowledge-sharing and collaboration in oncology.
“I would like to thank the many OCC members and fellow stakeholders who joined us last week. Your participation strengthens our ecosystem. A special acknowledgement to OCC Members BMS and Kite, A Gilead Company for sponsoring this event, helping to make a meeting at this scale, possible.”
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific, is the latest addition to the board of Oslo Cancer Cluster.